{"schema_version":"1.0","type":"article","title":"Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?","url":"https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.md","lang":"en","date":"2026-06-26","publish_at":"2026-06-26T10:30:00+08:00","updated_at":"2026-06-26","category":"商業分析系列","topic":"商業分析系列","tags":["GLP-1","tirzepatide","Zepbound","Taltz","Omvoh","immunometabolism","autoimmune disease","psoriasis","IBD","Eli Lilly","biotech investing"],"summary":"Lilly is testing whether tirzepatide can move beyond weight loss and become part of an immunometabolism strategy for chronic immune-inflammatory diseases.","key_points":[],"facts":[],"sections":["1. Zepbound plus Taltz is not just a weight-loss study","2. Why psoriasis and psoriatic arthritis are natural first tests","3. The real thesis is immunometabolism","4. Lilly is not stopping at skin and joints","5. Autoimmune disease is still a market with money","6. What tirzepatide could give Lilly","7. What investors should not overstate","8. Taiwan angle","Bottom line","References"],"references":[{"title":"Lilly. Zepbound prescribing information.","source":"","date":"","url":"https://uspl.lilly.com/zepbound/zepbound.html#pi"},{"title":"Lilly. Taltz prescribing information.","source":"","date":"","url":"https://uspl.lilly.com/taltz/taltz.html#pi"},{"title":"Lilly. COMMIT-CD clinical trial page.","source":"","date":"","url":"https://trials.lilly.com/en-US/trial/600156"},{"title":"Lilly. Omvoh prescribing information.","source":"","date":"","url":"https://uspl.lilly.com/omvoh/omvoh.html#pi"},{"title":"AbbVie. Rinvoq prescribing information.","source":"","date":"","url":"https://www.rxabbvie.com/pdf/rinvoq_pi.pdf"},{"title":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","source":"","date":"","url":""}],"images":[{"alt":"Tirzepatide moves into immunometabolism","url":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/figure-01.png"},{"alt":"Combination trial logic for Zepbound and Taltz","url":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/figure-02.png"},{"alt":"Immunometabolism loop between obesity and inflammation","url":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/figure-03.png"},{"alt":"Commercial logic for Lilly's tirzepatide expansion","url":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-26）。Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?。https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-26-tirzepatide-autoimmune-immunometabolism.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}